✦ LIBER ✦

The effect of pathological response of multicenter phase II trial of fluorouracil, epirubicin, cyclophosphamide (FEC 100) followed by docetaxel (DOC 75) in primary operable breast cancer (JBCRG01: Japan Breast Cancer Research Group)

✍ Scribed by S. Nakamura; Toi; Y. Takatsuka; K. Kuroi; H. Iwata; S. Ohno; N. Masuda; H. Tsuda; M. Kurosumi; F. Akiyama

Book ID: 118624669
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 136 KB
Volume: 4
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(06)80390-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Neoadjuvant docetaxel (DOC 75) followed

Neoadjuvant docetaxel (DOC 75) followed by fluorouracil, epirubicin, cyclophosphamide (FEC 100) in primary operable breast cancer: results of a multicenter phase II trial

✍ N. Sato; H. Iwata; N. Masuda; S. Nakamura; N. Yamamoto; K. Kuroi; M. Kurosumi; H 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 56 KB

Phase 2 trial of primary systemic therap

Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer : Long-term results from The University of Texas M. D. Anderson Cancer Center Study ID97-099

✍ Ricardo H. Alvarez; Daniel J. Booser; Massimo Cristofanilli; Aysegul A. Sahin; E 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB 👁 2 views